000021473 001__ 21473
000021473 005__ 20210129210801.0
000021473 0247_ $$2pmid$$apmid:21592320
000021473 0247_ $$2DOI$$a10.1111/j.1755-5949.2011.00247.x
000021473 0247_ $$2WOS$$aWOS:000300001700008
000021473 0247_ $$2altmetric$$aaltmetric:239214
000021473 037__ $$aPreJuSER-21473
000021473 041__ $$aeng
000021473 082__ $$a610
000021473 084__ $$2WoS$$aNeurosciences
000021473 084__ $$2WoS$$aPharmacology & Pharmacy
000021473 1001_ $$0P:(DE-HGF)0$$aBurghaus, L.$$b0
000021473 245__ $$aHallucinations in neurodegenerative diseases
000021473 260__ $$aOxford$$bWiley-Blackwell$$c2012
000021473 300__ $$a149 - 159
000021473 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article
000021473 3367_ $$2DataCite$$aOutput Types/Journal article
000021473 3367_ $$00$$2EndNote$$aJournal Article
000021473 3367_ $$2BibTeX$$aARTICLE
000021473 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000021473 3367_ $$2DRIVER$$aarticle
000021473 440_0 $$026564$$aNeurosciences and Therapeutics$$v18$$y2
000021473 500__ $$aRecord converted from VDB: 12.11.2012
000021473 520__ $$aPatients with neurodegenerative disease frequently experience hallucinations and illusionary perceptions. As early symptoms, hallucinations may even have diagnostic relevance (i.e., for the diagnosis of Lewy Body Dementia). In the later course of the disease, hallucinations may appear as characteristic symptoms and often constitute a particular challenge for therapeutic endeavors. Here, the distinction of disease-inherent hallucinations from medication-associated perceptual disturbances is particularly relevant. Synucleinopathies and tauopathies have different risk profiles for hallucinations. In synucleinopathies hallucinations are much more frequent and phenomenology is characterized by visual, short-lived hallucinations, with insight preserved for a long time. A “double hit” theory proposes that dysfunctionality of both associative visual areas and changes of limbic areas or the ventral striatum are required. In contrast, in tauopathies the hallucinations are more rare and mostly embedded in confusional states with agitation and with poorly defined or rapidly changing paranoia. The occurrence of hallucinations has even been proposed as an exclusion criterion for tauopathies with Parkinsonian features such as progressive supranuclear palsy. To date, treatment remains largely empirical, except the use of clozapine and cholinesterase inhibitors in synucleinopathies, which is evidence-based. The risk of increased neuroleptic sensitivity further restricts the treatment options in patients with Lewy Body Dementia. Coping Strategies and improvement of visual acuity and sleep quality may be useful therapeutic complements.
000021473 536__ $$0G:(DE-Juel1)FUEK409$$2G:(DE-HGF)$$aFunktion und Dysfunktion des Nervensystems (FUEK409)$$cFUEK409$$x0
000021473 536__ $$0G:(DE-HGF)POF2-89572$$a89572 - (Dys-)function and Plasticity (POF2-89572)$$cPOF2-89572$$fPOF II T$$x1
000021473 588__ $$aDataset connected to Web of Science, Pubmed
000021473 650_2 $$2MeSH$$aAdaptation, Psychological
000021473 650_2 $$2MeSH$$aAnimals
000021473 650_2 $$2MeSH$$aHallucinations: epidemiology
000021473 650_2 $$2MeSH$$aHallucinations: psychology
000021473 650_2 $$2MeSH$$aHallucinations: therapy
000021473 650_2 $$2MeSH$$aHumans
000021473 650_2 $$2MeSH$$aNeurodegenerative Diseases: epidemiology
000021473 650_2 $$2MeSH$$aNeurodegenerative Diseases: psychology
000021473 650_2 $$2MeSH$$aNeurodegenerative Diseases: therapy
000021473 650_2 $$2MeSH$$aParkinson Disease: epidemiology
000021473 650_2 $$2MeSH$$aParkinson Disease: psychology
000021473 650_2 $$2MeSH$$aParkinson Disease: therapy
000021473 650_2 $$2MeSH$$aSleep Disorders: epidemiology
000021473 650_2 $$2MeSH$$aSleep Disorders: psychology
000021473 650_2 $$2MeSH$$aSleep Disorders: therapy
000021473 650_7 $$2WoSType$$aJ
000021473 65320 $$2Author$$aAlzheimer's disease
000021473 65320 $$2Author$$aCorticobasal degeneration
000021473 65320 $$2Author$$aDementia with Lewy bodies
000021473 65320 $$2Author$$aFrontotemporal dementia
000021473 65320 $$2Author$$aHallucinations
000021473 65320 $$2Author$$aMultiple system atrophy
000021473 65320 $$2Author$$aNeurodegenerative diseases
000021473 65320 $$2Author$$aParkinson's disease
000021473 65320 $$2Author$$aProgressive supranuclear palsy
000021473 65320 $$2Author$$aSynucleinopathy
000021473 65320 $$2Author$$aTauopathy
000021473 7001_ $$0P:(DE-HGF)0$$aEggers, C.$$b1
000021473 7001_ $$0P:(DE-HGF)0$$aTimmermann, L.$$b2
000021473 7001_ $$0P:(DE-Juel1)131720$$aFink, G.R.$$b3$$uFZJ
000021473 773__ $$0PERI:(DE-600)2423467-9$$a10.1111/j.1755-5949.2011.00247.x$$gVol. 18, p. 149 - 159$$p149 - 159$$q18<149 - 159$$tCNS neuroscience & therapeutics$$v18$$x1755-5949$$y2012
000021473 8567_ $$uhttp://dx.doi.org/10.1111/j.1755-5949.2011.00247.x
000021473 909CO $$ooai:juser.fz-juelich.de:21473$$pVDB
000021473 9132_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000021473 9131_ $$0G:(DE-HGF)POF2-89572$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$v(Dys-)function and Plasticity$$x1
000021473 9141_ $$y2012
000021473 915__ $$0StatID:(DE-HGF)0040$$2StatID$$aPeer review unknown
000021473 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR
000021473 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000021473 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000021473 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000021473 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000021473 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000021473 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000021473 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000021473 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000021473 9201_ $$0I:(DE-Juel1)INM-3-20090406$$gINM$$kINM-3$$lKognitive Neurowissenschaften$$x0
000021473 970__ $$aVDB:(DE-Juel1)137463
000021473 980__ $$aVDB
000021473 980__ $$aConvertedRecord
000021473 980__ $$ajournal
000021473 980__ $$aI:(DE-Juel1)INM-3-20090406
000021473 980__ $$aUNRESTRICTED